Increased reporting of ILD emerged for CDK4/6 inhibitors as a class, when compared to all other drugs recorded in the FAERS database (ROR = 1.50; 95%CI = 1.28–1.74). This evidence concerns the gene CDK4 and interstitial lung disease.